HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
Summary: Treatment-Naive Genotype 1a With Compensated Cirrhosis
Recommended and alternative regimens listed by evidence level and alphabetically for:
Treatment-Naive Genotype 1a Patients With Compensated Cirrhosisa
RECOMMENDED
DURATION
RATING
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASsb for elbasvir
12 weeks
I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)c
12 weeks
I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)
12 weeks
I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)
12 weeks
I, A
ALTERNATIVE
DURATION
RATING
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) with weight-based ribavirin for patients with baseline NS5A RASsb for elbasvir
16 weeks
IIa, B
a For decompensated cirrhosis, please refer to the appropriate section. b Includes genotype 1a resistance-associated substitutions at amino acid positions 28, 30, 31, or 93 known to confer antiviral resistance. c This is a 3-tablet coformulation. Please refer to the prescribing information.
